There is an increasing recognition that inflammation plays a critical role in
neurodegenerative diseases of the CNS, including Alzheimer's disease, amyotrophic lateral …

Selective depletion of CD20+ B cells by anti-CD20 monoclonal antibodies as monotherapy
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …

Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …

Objective To perform a meta-analysis of randomized, blinded, multiple sclerosis (MS) clinical
trials, to test the hypothesis that efficacy of immunomodulatory disease-modifying therapies …

The clinical success of anti-CD20 monoclonal antibody (mAb)-mediated B cell depletion
therapy has contributed to the understanding of B cells as major players in several …

Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes
of drugs in recent years and are approved for the treatment of a wide range of indications …

B cells mediate multiple sclerosis (MS) pathogenesis by mechanisms unrelated to
immunoglobulin (Ig). We reported that supernatants (Sup) from cultured B cells from blood of …

Highly effective anti-inflammatory therapies have so far been developed for patients with
relapsing/remitting multiple sclerosis, which also show some benefits in the early …

B cells, plasma cells and antibodies may play a key role in the pathogenesis of multiple
sclerosis (MS). This notion is supported by various immunological changes observed in MS …

A role of B cells in multiple sclerosis (MS) is well established, but there is limited
understanding of their involvement during active disease. Here, we examined cerebrospinal …